Sunrise Realty Trust, Inc. Common Stock When-Issued
SUNSV News Today: Stay Updated with the Latest Sunrise Realty Trust, Inc. Common Stock When-Issued News in Real Time
Find SUNSV news now at Meyka AI. Stay informed with the latest Sunrise Realty Trust, Inc. Common Stock When-Issued stocks updates, including price news, market analysis, and expert insights.
3608.HK Stock Surges on 2,349% Volume Spike, 22 Apr 2026
3608.HK stock jumps 1.02% on massive 782,500 share volume spike. Yongsheng Advanced Materials trades at HK$0.99 on HKSE.
IFX.DE Stock Gains 2.47% on XETRA; Infineon at €49.18
IFX.DE stock rises 2.47% to €49.18 on XETRA. Infineon Technologies AG shows mixed signals with B- rating and upcoming earnings on May 6.
MLEC Insider Filing: Core Daniel Joaquin Director Stake, April 22, 2026
Director Core Daniel Joaquin files initial ownership of 933 ordinary shares in Moolec Science (MLEC) valued at $6,661.62 on April 15, 2026.
5IF.SI Stock Drops 13.6% on Apr 22, 2026 as Natural Cool Holdings Faces Pressure
5IF.SI stock falls 13.6% to S$0.089 on Apr 22, 2026. Natural Cool Holdings faces headwinds with weak fundamentals and high debt levels.
DW8.AX Stock Surges 2400% in April 2026 on ASX
DW8.AX stock price hits A$0.025 with massive 2400% gain. Beverage tech platform shows extreme volatility on ASX.
GNRSU Stock Crashes 99.99% on Pink Sheets, Greenrose Holdings Faces Delisting Risk
GNRSU stock plummets 99.99% to $0.000001 on PNK exchange. Greenrose Holdings faces severe liquidity crisis with market cap of just $13.
PASHUPATI.NS Stock Plunges 14.5% on NSE; Textile Maker Hits 22 Apr Close
PASHUPATI.NS stock fell 14.5% to INR 81.95 on NSE today. Pashupati Cotspin faces strong sell rating with weak technical signals.
GRBK Insider Trading: Cox Jeffery Dean Restricted Stock Units Filing April 22, 2026
Green Brick Partners insider Jeffery Dean files restricted stock units ownership. GRBK rated B+ by Meyka AI. SEC filing details.
Travere Kidney Drug Approved April 22: FDA Flexes Authority
Travere’s Filspari approved by FDA April 22 for rare kidney disease, opening a $3B market opportunity despite limited efficacy data.